[#item_full_content] Trulieve Cannabis (CNSX:TRUL) remains unprofitable, with losses compounding at an annual rate of 41% over the past five years. Revenue is projected to grow just 2.6% per year, lagging well behind the Canadian market’s 5.1% pace. The company’s price-to-sales ratio of 1.1x provides a modest value relative to peers but remains a bit steep compared to the broader pharmaceuticals industry at 1x. For investors, the persistent unprofitability and slow revenue uplift mean the path to profitability is… Read More
